These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2190972)

  • 1. Treatment of experimental Salmonella typhimurium infection in mice with lomefloxacin.
    Butler T; Cartagenova M; Dunn D
    J Antimicrob Chemother; 1990 Apr; 25(4):629-34. PubMed ID: 2190972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rufloxacin in Salmonella typhimurium infection in mice.
    Bonina L; Carbone M; Mastroeni P; Costa GB; Mastroeni P
    J Chemother; 1992 Dec; 4(6):353-7. PubMed ID: 1337552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days.
    Gros I; Carbon C
    Antimicrob Agents Chemother; 1990 Jan; 34(1):150-2. PubMed ID: 2327750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on: Effect of a 5 day enrofloxacin treatment on Salmonella enterica serotype Typhimurium DT104 in the pig.
    Silley P; Froyman R
    J Antimicrob Chemother; 2004 Sep; 54(3):692-3; author reply 693-4. PubMed ID: 15308603
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and safety of single oral doses of lomefloxacin.
    Morse IS
    Biopharm Drug Dispos; 1990; 11(6):543-51. PubMed ID: 2207304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue penetration of orally administered lomefloxacin.
    Stone JW; Andrews JM; Ashby JP; Griggs D; Wise R
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1508-10. PubMed ID: 3190181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs.
    Wiuff C; Lykkesfeldt J; Svendsen O; Aarestrup FM
    Res Vet Sci; 2003 Dec; 75(3):185-93. PubMed ID: 13129666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers.
    Leigh DA; Harris C; Tait S; Walsh B; Hancock P
    J Antimicrob Chemother; 1991 May; 27(5):655-62. PubMed ID: 1885423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Typhoid fevers: treatment with lomefloxacin.
    Hafiz S; Habib F; Ahmad N; Haq I; Husain R
    J Pak Med Assoc; 1998 Jun; 48(6):168-70. PubMed ID: 9813988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy trials with enrofloxacin (Baytril) in a laying hen flock with Salmonella pullorum infections].
    Redmann T; Glünder G; Schildger B; Göbel T; Kaleta EF
    Dtsch Tierarztl Wochenschr; 1989 Mar; 96(3):137-8. PubMed ID: 2651079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man.
    Wijnands GJ; Cornel JH; Martea M; Vree TB
    Chest; 1990 Dec; 98(6):1440-4. PubMed ID: 2245687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.
    Kavi J; Stone J; Andrews JM; Ashby JP; Wise R
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):168-70. PubMed ID: 2498102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lomefloxacin clinical pharmacokinetics.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    Clin Pharmacokinet; 1993 Jul; 25(1):6-19. PubMed ID: 8394795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
    Hof H; Fabrig J
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():123-7. PubMed ID: 3144530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lomefloxacin on the normal oral and intestinal microflora.
    Edlund C; Brismar B; Nord CE
    Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):35-9. PubMed ID: 2303064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of interaction between lomefloxacin and caffeine in normal volunteers.
    Healy DP; Schoenle JR; Stotka J; Polk RE
    Antimicrob Agents Chemother; 1991 Apr; 35(4):660-4. PubMed ID: 2069371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentrations of oral lomefloxacin in serum and bronchial mucosa.
    Baldwin DR; Honeybourne D; Andrews JM; Ashby JP; Wise R
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1017-9. PubMed ID: 2393260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of lomefloxacin following multiple doses.
    Hunt TL; Adams MA
    Diagn Microbiol Infect Dis; 1989; 12(2):181-7. PubMed ID: 2752716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostatic tissue and fluid levels of lomefloxacin (NY-198)].
    Nasu Y; Nishitani Y; Yamada D; Hayata S; Tsugawa M; Kishi M; Mizuno A; Kumon H; Ohmori H; Nanba K
    Hinyokika Kiyo; 1989 Mar; 35(3):551-6. PubMed ID: 2735259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.